50 results about "Bladder Tissue" patented technology

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

Embodiments for an anchor for use in effecting the anastomosis of a patient's bladder and urethra following a prostatectomy are disclosed. The anchor may comprise a shaft with a lodging structure. Alternative embodiments may include a penetration limiting structure, a driver interface proximate to a rearward end, a forward end with a penetration facilitating shape that may comprise a point defined by three flat intersecting faces, a bioabsorbable portion of one or more bioabsorbable materials, and a metal portion of one alloy, or a plurality of alloys which may have differing expansion properties.

Regions of tissue having reduced electrical propagation are created in a bladder to affect its electrical or mechanical properties. To create these tissue regions, a tubular device is advanced through the urethra leading to the interior of the bladder, a distal expandable structure of the device is expanded to contact the inner wall of the bladder, and electrodes or other active energy delivery elements of the device are activated to deliver ablation energy. The electrodes or other active energy delivery elements are disposed over the expandable structure which is shaped to conform to the interior of the bladder. The inner wall of the organ is ablated in a predetermined pattern. The same or other electrodes disposed over the expandable structure can used to electrically map the bladder. This map of electrical activity can be used to create the predetermined pattern.

Methods, devices, and medicaments that include oxaliplatin are provided for use in the treatment of bladder cancer by locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue. The oxaliplatin may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the oxaliplatin into the urine in the bladder over an extended period of hours or days.

The invention relates to a method for preparing swimming bladder collagen powder. The method comprises the following steps: by taking dry swimming bladders as a raw material, washing, ordinarily crushing, soaking in water, further performing ultrasonic treatment, adding water to pulp to prepare swimming bladder pulp, adding papain to control enzyme enzymolysis, performing enzyme deactivation, centrifuging, filtering, and feeding the supernate into a spray-drying tower for spray-drying, thereby obtaining the swimming bladder collagen powder. According to the method, as ultrasonic auxiliary treatment and enzyme engineering techniques are adopted, the processing condition is gentle, the reaction process is easy to control, the swimming bladders are treated by using ultrasonic waves before enzymolysis so as to break the swimming bladder tissue and the cytomembranes, bio-enzyme can contact protein, the enzymolysis efficiency is improved, the process is advanced and reasonable, and because of the bio-enzyme, the rich protein in the swimming bladders can be converted into amino acid which is easy to digest and absorb by human bodies. The method is advanced in process and feasible in operation, the production cost is lowered, the product quality is improved, and the digestion rate is increased.

The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2 / DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

Methods, devices, and medicaments that include trospium are provided for use in the treatment of bladder dysfunction by locally administering the trospium into the bladder to achieve a sustained concentration of trospium in urine in the bladder sufficient to produce a therapeutic concentration of trospium in bladder tissue. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

A vapor delivery system and method is provided that is adapted for ablating bladder tissue to treat overactive bladder (OAB). The vapor delivery system includes an anchor tip configured anchor the system in the bladder while condensable vapor is delivered to target tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the target tissue of the bladder, which can include a surface sensor of the bladder responsible for creating an urge incontinence sensation. The vapor delivery system includes a vapor source that provides a high quality vapor for delivery to tissue.

Regions of tissue having reduced electrical propagation are created in a bladder to affect its electrical or mechanical properties. To create these tissue regions, a tubular device is advanced through the urethra leading to the interior of the bladder, a distal expandable structure of the device is expanded to contact the inner wall of the bladder, and electrodes or other active energy delivery elements of the device are activated to deliver ablation energy. The electrodes or other active energy delivery elements are disposed over the expandable structure which is shaped to conform to the interior of the bladder. The inner wall of the organ is ablated in a predetermined pattern. The same or other electrodes disposed over the expandable structure can used to electrically map the bladder. This map of electrical activity can be used to create the predetermined pattern.

The present invention discloses a preparation method of a soft tissue decellular matrix, and relates to the technical field of clinical medicine, biomedical medicine and regenerative medicine. According to the present invention, the natural soft tissue decellular matrix is prepared by using a supercritical fluid technology, wherein the natural soft tissue comprises small intestine tissue, blood vessel tissue, muscle tissue, heart tissue, valve tissue, lung tissue, spleen tissue, kidney tissue, liver tissue, stomach tissue, gallbladder tissue, fat tissue, cartilage tissue, trachea tissue, esophagus tissue, bladder tissue, ureter tissue, oviduct tissue, or uterus tissue. According to the present invention, with the preparation method, the damage on the soft tissue matrix component is low, and the obtained soft tissue decellular matrix has advantages of low immunogenicity and good biocompatibility.

The present invention relates to a 3 dimensional mimetic tissue structure—“Assembloid” based on patient-derived multiple cell types to develop next generation organoid technology serving as a novel platform for new drug development and a disease model and a method of manufacturing the same, and more particularly, to a stem cell- or tumor cell-based 3D multicellular mimetic tissue structure manufactured by reconstituting epithelial or tumor cells with various cellular components of a microenvironment such as stromal cells, vascular cells, immune cells or muscle cells based on three-dimensional (3D) bioprinting, and a method of manufacturing the same. As the stem cell- or tumor cell-based 3D multicellular mimetic tissue structure containing the major factors of a tissue microenvironment, such as stromal cells, vascular cells, immune cells and muscle cells, designed according to the present invention is confirmed to mimic physiological and pathological characteristics of tissue in the body better than conventional organoids, normal and tumor assembloids may be used as a new platform for new drug development and a disease model. More specifically, together with 3D bioprinting technology, it is expected that in vitro bladder tissue and bladder tumor tissue are effectively used as a platform to develop precise and personalized therapeutic options for bladder related diseases including bladder cancer.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and / or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.

The invention relates to a method for constructing an air bladder cell system of blotchy rockcod, which comprises: taking an air bladder tissue of the blotchy rockcod as a material to start primary culture, and culturing the air bladder tissue in a DMEM / F12 liquid medium which contains fetal calf serum, carboxymethyl chito-oligosaccharide, basic fibroblast growth factors, I-type insulin-like growth factors, N-acetyl glucose hydrochloride and culture supernatant of heart cells of the blotchy rockcod in the log phase and has a pH value of between 7.0 and 7.4; and adopting a trypsin digestion method for subculturing. The air bladder cell system of the blotchy rockcod constructed by the method is subcultured for 62 generations currently. The technology is scientific and reasonable, is hopeful to be applied to ecotoxicological research, performs pollution monitoring and safety evaluation on various environmental pollutants in the sea, and can also be applied to separation, identification and in vitro breeding of fish viroids, and research in the aspects of interaction of viruses and host cells, and so on.

The invention provides a bladder membrane biological scaffold preparation method. The method comprises the following steps: 1) using NaOH for processing bladder tissues; 2) using TritonX-100 and SDS for processing the bladder tissues with any sequence, repeating the step; 3) using NaOH for processing the bladder tissues; and 4) drying the product at low temperature. In the method, a protease inhibitor can be used for processing the bladder tissues before the step 1), and nuclease can be used for processing the bladder tissues after processing by TritonX-100 and SDS in the step 2). The prepared bladder membrane biological scaffold has good biocompatibility and mechanical strength, and provides a tissues regenerating framework, and has the advantages that bacteria and virus can be thoroughly killed, the rejection is little, and the bladder membrane biological scaffold can be used for bladder restoration.

The invention provides a preparation apparatus of the Bladder Acellular Matrix (BAM) by simulating a physiological process. The apparatus comprises the jars, the silicone tubes, the peristaltic pumps,the T-joints, the perfusion needles, and a bladder-like part with 'ureters' and 'urethras'. After the two perfusion needles are connected to the 'ureter' on both sides of the bladder-like part, the bladder-like part is suspended and fixed. Two jars with decellularized liquid are connected with two silicone tubes, wherein the grooves of the two peristaltic pumps are pressed by the tubes. The otherend of the two silicone tubes are respectively connected with two T-joints, and the needle cap part of the perfusion needles connected to the 'ureters' are respectively connected to the two T-jointsto complete the assembly of the preparation apparatus for the BAM. The BAM preparation by the apparatus is fast, and the cell components of the bladder-like part are removed to the maximum extent while preserving as much as possible the composition and structure of the extracellular matrix. The apparatus can effectively simulate the physiological process of the bladder tissue and prepare the BAM quickly and efficiently.

The invention discloses a training model and method for the minimally-invasive surgery of a low urinary tract for urinary surgery. The model comprises a support, and is characterized in that the model also comprises a transparent bladder ball model which is disposed on the support, is used for simulating bladder tissues of a human body and is provided with a bladder inner cavity; the transparent bladder ball model is connected with a prostate model which is used for simulating hyperplastic prostate tissues of the human body, is provided with a prostate inner cavity and can be opened and closed; the rear part of the prostate model is connected with the transparent bladder ball model; the tip of the prostate model is connected with a urethra model; an inner wall of the prostate model is provided with prostate tissues for simulating hyperplasia. The model is simple in structure, is low in cost, is convenient to operate, employs detachable connection, is more convenient to use, can improve the operation success rate of a beginner through repeated practice, and is especially suitable for popularization and application.

Tissue compression devices including a multi-chamber bladder that is retained within the tissue compression device, with the multi-chamber bladder being positioned in a bladder orifice in a base of a compression device body. The multi-chamber bladder includes at least one upper chamber located above the base and at least one lower chamber located below the base. The lower chamber is located between the base and a selected location on a patient when the compression device is positioned over selected tissue such as, e.g., a radial artery, as described herein.

The invention relates to an application of DHFR in bladder cancer detection, and belongs to the technical field of molecular biology gene detection. The application includes the following steps: 1, respectively extracting DNA from the bladder tissue and peripheral blood of a sample to obtain DNA templates; 2, respectively carrying out real-time quantitative PCR amplification on the DNA extracted from the bladder tissue and peripheral blood of the sample with a primer pair P as a primer; and 3, calculating the log2 ratio of the sample according to delta delta Ct, and comparing the log2 ratio with copy number variation obtained by using whole genome sequencing data, and determining as a bladder cancer sample when the copy number variation is more than 2.5 or is less than 1.5 or when a G fraction obtained through an GISTIC algorithm is more than 0.08 or is less than 0.08. In the invention, sequence amplified DHFR can be used as a marker for the bladder cancer detection; and DHFR gene can be used as a gene target treatment kit of the bladder cancer.

The invention belongs to the technical field of biological medicine, and discloses a bladder targeted drug-loaded exosome and application as well as a drug for treating bladder diseases. The drug for treating bladder diseases is introduced into the exosome with bladder tissue targeting property to obtain the exosome, and the exosome with bladder tissue targeting property is derived from kidney cells; and a bladder tumor treatment drug contains the bladder targeted drug-loaded exosome. Compared with the prior art, the exosome secreted by the kidney cells can be enriched in the bladder tissue without any modification, the exosome derived from the kidney cells is used, the problem of exosome yield is solved, and the application prospect is very good; and the exosome from the kidney cells can be used for loading different drugs or active molecules, through targeted bladder tissue administration, the treatment effect on bladder diseases is improved, and toxic and side effects of the drugs are reduced.

The invention discloses a side balloon urinary catheter for preventing clogging and preventing urine leakage. The side balloon urinary catheter includes a second connection seat, a flow guiding tube,a first connection seat, a first catheter, a telescopic tendon body, a balloon bag, a second catheter, a balloon, a urinary catheterization port and an end cap. According to the side balloon urinary catheter, a balloon ball tightly adheres to bladder tissue by injecting water into the balloon, the effect of squeezing urine out of a urination port is achieved by controlling the internal pressure ofthe bladder; a method of arranging the balloon bag and the telescoping tendon body is adopted, the balloon bag is expanded through a method of injecting water or air into the balloon bag, the telescoping tendon body is expanded, and the telescoping tendon body is close to urethra of a patient, the effect that urine is prevented from flowing between the urethra and the outer wall of the catheter is achieved, the telescopic tendon body avoids the problems of over-expansion and uneven expansion of the balloon bag, and the side balloon urinary catheter has the characteristics that operation is simple, the patient has less pain, and lateral flow of urine is prevented.

The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2 / DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

A vapor delivery system and method is provided that is adapted for ablating bladder tissue to treat overactive bladder (OAB). The vapor delivery system includes an anchor tip configured anchor the system in the bladder while condensable vapor is delivered to target tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the target tissue of the bladder, which can include a surface sensor of the bladder responsible for creating an urge incontinence sensation. The vapor delivery system includes a vapor source that provides a high quality vapor for delivery to tissue.

Devices, system and methods for heating pelvic floor tissues are provided. The devices of the present invention can be used to apply heat to pelvic floor tissues such as rectal, vaginal, urethral and / or bladder tissues in order to treat disorders associated with such tissues.

The invention discloses a bladder-cancer specific oncolytic adenovirus independent of CAR, an establishment method and application and belongs to the technical field of biological genetic engineering. Multiple cloning site linkers are made by artificially synthesizing DNA oligonucleotide fragments, expression of an oncolytic adenovirus EIA gene is controlled based on a specific promoter UPII of the urinary bladder, a prostate stem cell antigen enhancer PSCAE is inserted into the upstream of the promoter UPII to enhance the activity of the promoter UPII, and the bladder-cancer specific oncolytic adenovirus Ad5 / F11p-PSCAE-UPII-E1A is established, can remarkably inhibit proliferation of CAR low-expression bladder cancer cells, has the bladder cancer specificity replication ability and has dose and time dependence.

Hypotonic formulations and methods for delivering drugs to bladder, improving drug absorption and retention therein, and minimizing systemic toxicity, are provided. The formulation includes particles formed from the assembly or association between biocompatible polymers with and without low or high grafting density of polyethylene glycol (PEG) and a wide range of drugs. A hypotonic medium or water allows the particles to penetrate and distribute within bladder tissue, where the particles are capable of dissolution to release drugs for absorption and retention. A reduced level of local and systemic toxicity and side effects of the formulation, compared to delivery of drugs in their free form, provides an effective and safe drug delivery platform for treating bladder or associated diseases or disorders.

The invention relates to a back-suction preventive bladder irrigator, comprising an irrigating tube, an irrigating liquid balloon and a rubber balloon. The rubber balloon is provided with protrusions formed integrally with the rubber balloon. The rubber balloon is provided with a rubber connecting tube. The irrigating liquid balloon is provided with a first connecting tube and a second connecting tube. The first connecting tube is connected with the irrigating tube. One end of the irrigating tube is connected with a silicone valve, and the other end thereof is connected with an irrigating connector. The silicone valve is funnel shaped, a large end face of the silicone valve is connected with the irrigating tube, and a small end face of the silicone valve is disposed in the first connecting tube. The silicone valve is composed of a valve flap which is provided with a strainer. The strainer is inwardly concave or outwardly convex. The back-suction preventive bladder irrigator has the advantages that the cost is low, the irrigator is handy, disposable and tolerant to high-temperature sterilizing and is suitable for fully irrigating the bladder, prostate or bladder tissues are avoided being sucked back into the bladder, the surgical time is shortened, surgical risk is decreased, and the irrigator has a promising clinical application prospect.

The invention provides a method for using centrifugal planting to construct a tissue engineering bladder. The method comprises the steps of using centrifugal planting equipment to prepare a bladder acellular matrix-seed cell suspension liquid structure; placing the bladder acellular matrix-seed cell suspension liquid structure in a centrifugal machine, wherein the centrifugal machine conducts centrifugal running for a specified time at a specified rotation speed; placing a centrifuged bladder acellular matrix in a culture dish, and using the cultured bladder acellular matrix to construct the tissue engineering bladder. The centrifugal planting equipment is constructed, and the proper rotation speed and the centrifugal planting time of the centrifugal machine are sought. Compared with common static planting and dynamic planting modes like pressure perfusion planting and rotary flask planting, centrifugal planting needs fewer cells; meanwhile, through centrifugal force, the seed cells can be uniformly distributed on the inner wall of a support, so that the planting cells enter the bladder acellular matrix, three-dimensional planting is formed, and the prepared tissue engineering bladder more fits actual bladder tissue.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and / or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.